Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00585637 · ClinicalTrials.gov registry record · Phase 1

Vitamin D for Chemoprevention

A Phase 1 study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
328
Enrollment target

NCT00585637: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.

NCT00585637 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 328 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (447% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00585637, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
328 participants
Enrollment target

Study Summary

This study will help us know the effects of Vitamin D pills in Blacks. The results of this study may be the first step in creating ways to prevent the risks of colon and prostate cancer. It will also help us develop ways to reduce colon cancer and prostate cancer among Blacks. This study will find out if Vitamin D pills can increase Vitamin D to healthy levels in our bodies.

Primary Outcome

Among Blacks, identify a dose of oral vitamin D supplementation that will result in levels of plasma 25(OH)D that would be predicted to reduce colorectal cancer incidence. Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DRUG Vitamin D

Trial Details

FieldValue
Enrollment Target 328 participants
Start Date 2007-10
Est. Completion 2013-12
Phase Phase 1
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00585637 record still lists

NCT00585637 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (447% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00585637 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00585637 about?

NCT00585637 is a clinical study titled "Vitamin D for Chemoprevention". This study will help us know the effects of Vitamin D pills in Blacks. The results of this study may be the first step in creating ways to prevent the risks of colon and prostate cancer. It will also help us develop ways to reduce colon cancer and prostate cancer among Blacks. This study will find o...

What is the current status of trial NCT00585637?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 328 participants. The study started on 2007-10. Estimated completion is 2013-12.

What interventions are being tested in trial NCT00585637?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Vitamin D (DRUG).

Who is sponsoring clinical trial NCT00585637?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00585637's enrollment target sits among peer trials

328 111th of 2000 higher than 1,890 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05156983 · 328 participants · Phase 3

    A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

  • NCT05380401 · 328 participants · NA

    Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

  • NCT05548413 · 328 participants · NA

    Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

  • NCT06393725 · 328 participants · NA

    Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00585637, the US trial registry maintained by the National Library of Medicine. NCT00585637 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.